Sometimes, when Amy is feeling nostalgic, she’s go to the Americana section of the grocery store in Australia and buy a Diet Dr. Pepper for, oh, about $2 a can.

The US Food and Drug Administration (FDA) has warned Dr Pepper Snapple Group (DPS) bottler the American Bottling Company after an inspection revealed serious HACCP failings at a Texas plant.

Beverage Daily reports that in a letter to the company dated July 10, but published last week, the FDA said an inspection of the firm’s facility in Irving, Texas revealed serious violations of Regulation 21, Code of Federal Regulations (CFR) Part 120, relating to juice hazard analysis and critical control points (HACCP).

“Your lemon and lime juices are adulterated in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health,” FDA Dallas District director Reynaldo R. Rodriguez wrote to American Bottling Company president and CEO Larry Young (who is also DPS CEO and president).

Recounting “serious deviations” at the site, the FDA told the managers that the company must include control measures in its hazard analysis and HACCP plan to “consistently produce at a minimum, a five-log* reduction of the pertinent microorganism for at least as long as the shelf life of the product when stored under normal and moderate abuse conditions.”

These were required under 21 CFR 120, the FDA wrote, but the company’s plan for its ReaLemon 100% Lemon Juice and ReaLime 100% Lime Juice brands did not provide such controls in relation to Listeria monocytogenes.

Only microbial verification studies relating to Salmonella and E.coli O157:H7 were evaluated, the FDA added, but “the pertinent microorganism in the juice from these concentrates is Listeria monocytogenes.”

“In addition, the study did not evaluate or identify the critical factors necessary for achieving a 5-log reduction (i.e. specific Brix, acidity, temperature, preservatives), and the time of holding necessary for achieving a 5-log reduction.”